A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies
Share this:
     
Published: 10 Nov 2014

This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.

  1.  
  2.  
  3.  
  4.  
  5.  
  6.  
  7.  
  8.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..